Haleon Stock (NYSE:HLN)
Previous Close
$10.32
52W Range
$7.70 - $10.40
50D Avg
$9.30
200D Avg
$8.58
Market Cap
$47.12B
Avg Vol (3M)
$3.88M
Beta
0.19
Div Yield
$0.16 (2.01%)
HLN Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
HLN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| LNTH | Lantheus Holdings, Inc. |
| HCM | HUTCHMED (China) Limited |
| EBS | Emergent BioSolutions Inc. |
| ELAN | Elanco Animal Health Incorporated |
| RDY | Dr. Reddy's Laboratories Limited |
| ESPR | Esperion Therapeutics, Inc. |
| VTRS | Viatris Inc. |
| NBIX | Neurocrine Biosciences, Inc. |
| TAK | Takeda Pharmaceutical Company Limited |
| BHC | Bausch Health Companies Inc. |
| TEVA | Teva Pharmaceutical Industries Limited |
| ZTS | Zoetis Inc. |
| CTLT | Catalent, Inc. |
| PETQ | PetIQ, Inc. |
| SIGA | SIGA Technologies, Inc. |